327 related articles for article (PubMed ID: 25989340)
1. Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy.
Huang VW; Prosser C; Kroeker KI; Wang H; Shalapay C; Dhami N; Fedorak DK; Halloran B; Dieleman LA; Goodman KJ; Fedorak RN
Inflamm Bowel Dis; 2015 Jun; 21(6):1359-67. PubMed ID: 25989340
[TBL] [Abstract][Full Text] [Related]
2. Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn's disease under infliximab therapy.
Cao WT; Huang R; Liu S; Fan YH; Xu MS; Xu Y; Ni H
World J Gastroenterol; 2022 Jun; 28(23):2582-2596. PubMed ID: 35949356
[TBL] [Abstract][Full Text] [Related]
3. Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance Infliximab Therapy.
Ferreiro-Iglesias R; Barreiro-de Acosta M; Otero Santiago M; Lorenzo Gonzalez A; Alonso de la Peña C; Benitez Estevez AJ; Dominguez-Muñoz JE
J Clin Gastroenterol; 2016 Feb; 50(2):147-51. PubMed ID: 25811118
[TBL] [Abstract][Full Text] [Related]
4. The long-term outcome of anti-tumor necrosis factor-α therapy related to fecal calprotectin values during induction therapy in pediatric inflammatory bowel disease.
Kolho KL; Sipponen T
Scand J Gastroenterol; 2014 Apr; 49(4):434-41. PubMed ID: 24597837
[TBL] [Abstract][Full Text] [Related]
5. Achieving Target Infliximab Drug Concentrations Improves Blood and Fecal Neutrophil Biomarkers in Crohn's Disease.
Colman RJ; Tsai YT; Jackson K; Boyle BM; Noe JD; Hyams JS; D'Haens GRAM; van Limbergen J; Rosen MJ; Denson LA; Minar P
Inflamm Bowel Dis; 2021 Jun; 27(7):1045-1051. PubMed ID: 32944769
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic drug monitoring was helpful in guiding the decision-making process for children receiving infliximab for inflammatory bowel disease.
Deora V; Kozak J; El-Kalla M; Huynh HQ; El-Matary W
Acta Paediatr; 2017 Nov; 106(11):1863-1867. PubMed ID: 28779489
[TBL] [Abstract][Full Text] [Related]
7. Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study.
Roblin X; Boschetti G; Duru G; Williet N; Deltedesco E; Phelip JM; Peyrin-Biroulet L; Nancey S; Flourié B; Paul S
Inflamm Bowel Dis; 2017 Nov; 23(11):2048-2053. PubMed ID: 28945636
[TBL] [Abstract][Full Text] [Related]
8. Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study.
Smits LJ; Derikx LA; de Jong DJ; Boshuizen RS; van Esch AA; Drenth JP; Hoentjen F
J Crohns Colitis; 2016 Nov; 10(11):1287-1293. PubMed ID: 27095751
[TBL] [Abstract][Full Text] [Related]
9. Infliximab Trough Levels Are Associated With Transmural Sonographic Healing in Inflammatory Bowel Disease.
Vaughan R; Murphy E; Nalder M; Gibson RN; Ardalan Z; Boussioutas A; Christensen B
Inflamm Bowel Dis; 2023 Jul; 29(7):1080-1088. PubMed ID: 36094156
[TBL] [Abstract][Full Text] [Related]
10. Success and safety of high infliximab trough levels in inflammatory bowel disease.
Drobne D; Kurent T; Golob S; Svegl P; Rajar P; Terzic S; Kozelj M; Novak G; Smrekar N; Plut S; Sever N; Strnisa L; Hanzel J; Brecelj J; Urlep D; Osredkar J; Homan M; Orel R; Stabuc B; Ferkolj I; Smid A
Scand J Gastroenterol; 2018 Aug; 53(8):940-946. PubMed ID: 29987967
[TBL] [Abstract][Full Text] [Related]
11. Exploration of Predictive Biomarkers of Early Infliximab Response in Acute Severe Colitis: A Prospective Pilot Study.
Beswick L; Rosella O; Rosella G; Headon B; Sparrow MP; Gibson PR; van Langenberg DR
J Crohns Colitis; 2018 Feb; 12(3):289-297. PubMed ID: 29121178
[TBL] [Abstract][Full Text] [Related]
12. Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission?
Molander P; Färkkilä M; Ristimäki A; Salminen K; Kemppainen H; Blomster T; Koskela R; Jussila A; Rautiainen H; Nissinen M; Haapamäki J; Arkkila P; Nieminen U; Kuisma J; Punkkinen J; Kolho KL; Mustonen H; Sipponen T
J Crohns Colitis; 2015 Jan; 9(1):33-40. PubMed ID: 25052347
[TBL] [Abstract][Full Text] [Related]
13. Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease.
Roblin X; Duru G; Williet N; Del Tedesco E; Cuilleron M; Jarlot C; Phelip JM; Boschetti G; Flourié B; Nancey S; Peyrin-Biroulet L; Paul S
Inflamm Bowel Dis; 2017 Jan; 23(1):126-132. PubMed ID: 28002129
[TBL] [Abstract][Full Text] [Related]
14. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy.
De Vos M; Louis EJ; Jahnsen J; Vandervoort JG; Noman M; Dewit O; Dʼhaens GR; Franchimont D; Baert FJ; Torp RA; Henriksen M; Potvin PM; Van Hootegem PP; Hindryckx PM; Moreels TG; Collard A; Karlsen LN; Kittang E; Lambrecht G; Grimstad T; Koch J; Lygren I; Coche JC; Mana F; Van Gossum A; Belaiche J; Cool MR; Fontaine F; Maisin JM; Muls V; Neuville B; Staessen DA; Van Assche GA; de Lange T; Solberg IC; Vander Cruyssen BJ; Vermeire SA
Inflamm Bowel Dis; 2013 Sep; 19(10):2111-7. PubMed ID: 23883959
[TBL] [Abstract][Full Text] [Related]
15. Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohn's disease.
Boschetti G; Garnero P; Moussata D; Cuerq C; Préaudat C; Duclaux-Loras R; Mialon A; Drai J; Flourié B; Nancey S
Inflamm Bowel Dis; 2015 Feb; 21(2):331-6. PubMed ID: 25625487
[TBL] [Abstract][Full Text] [Related]
16. Association Between Infliximab Trough Levels and the Occurrence of Paradoxical Manifestations in Patients with Inflammatory Bowel Disease: a Case-Control Study.
Coutzac C; Chapuis J; Poullenot F; Chabrun E; Capdepont M; Blanco P; Laharie D
J Crohns Colitis; 2015 Nov; 9(11):982-7. PubMed ID: 26351388
[TBL] [Abstract][Full Text] [Related]
17. A study investigating the association of dermatological and infusion reactions to infliximab and infliximab trough levels.
Huang V; Dhami N; Fedorak D; Prosser C; Shalapay C; Kroeker KI; Halloran BP; Dieleman LA; Fedorak RN
Can J Gastroenterol Hepatol; 2015; 29(1):35-40. PubMed ID: 25706572
[TBL] [Abstract][Full Text] [Related]
18. Potential of Fecal Calprotectin as an Objective Marker to Discriminate Hospitalized Patients with Acute Severe Colitis from Outpatients with Less Severe Disease.
Kedia S; Jain S; Goyal S; Bopanna S; Yadav DP; Sachdev V; Sahni P; Pal S; Dash NR; Makharia G; Travis SPL; Ahuja V
Dig Dis Sci; 2018 Oct; 63(10):2747-2753. PubMed ID: 29948556
[TBL] [Abstract][Full Text] [Related]
19. Clinical Use of Infliximab Trough Levels and Antibodies to Infliximab in Pediatric Patients With Inflammatory Bowel Disease.
Merras-Salmio L; Kolho KL
J Pediatr Gastroenterol Nutr; 2017 Feb; 64(2):272-278. PubMed ID: 27149256
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease.
Kelly OB; Donnell SO; Stempak JM; Steinhart AH; Silverberg MS
Inflamm Bowel Dis; 2017 Jul; 23(7):1202-1209. PubMed ID: 28498155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]